Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD

Link:

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical Psychiatry found once-daily VYVANSE significantly improved Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults within the first week of treatment.

Translate into: cs pl ru de ja nl es ar pt fr el it ko tr no fi hu sv ro hi bg et lt lt sk tl iw hr id ca lv sl sr uk vi
Link: http://www.medicalnewstoday.com/articles/124573.php
Complete RSS
<<< Back

Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD - témata

VYVANSE(R), Significantly, Improved, ADHD, Symptoms, One, The, Largest, Controlled, Stimulant, Trials, Adults, With, Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms, The Largest Controlled Stimulant Trials, Adults With ADHD , (LSE:, SHP, NASDAQ:, SHPGY), September, Journal, Clinical, Psychiatry, VYVANSE, Attention, Deficit, Hyperactivity, Disorder, (ADHD), Shire, (LSE: SHP, NASDAQ: SHPGY),, Clinical Psychiatry, Attention Deficit Hyperactivity Disorder (ADHD), Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD,

Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD

Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD - témata

RSS sources

Your own sources

Public sources